Ocular Therapeutix (OCUL) Total Non-Current Liabilities (2013 - 2026)

Ocular Therapeutix's Total Non-Current Liabilities history runs 11 years deep, the most recent figure standing at $150.0 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 18.95% year-over-year to $150.0 million in Q1 2026; TTM through Mar 2026 was $150.0 million, a 18.95% increase from a year earlier, with the FY2025 full-year figure at $139.8 million, down 1.83% from the prior year.
• Total Non-Current Liabilities climbed to $150.0 million in Q1 2026 per OCUL's latest filing, from $139.8 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $150.0 million in Q1 2026 and bottomed at $94.6 million in Q1 2022.
• The 5-year median for Total Non-Current Liabilities is $130.9 million (2023), against an average of $125.7 million.
• Across the five-year window, Total Non-Current Liabilities soared 42.07% in 2023 and declined 6.25% in 2024, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $113.8 million in 2022, then climbed by 15.05% to $130.9 million in 2023, then rose by 8.79% to $142.4 million in 2024, then slipped by 1.83% to $139.8 million in 2025, then advanced by 7.3% to $150.0 million in 2026.
• Per Business Quant, the three latest OCUL Total Non-Current Liabilities figures stand at $150.0 million (Q1 2026), $139.8 million (Q4 2025), and $137.7 million (Q3 2025).